Details
Stereochemistry | RACEMIC |
Molecular Formula | C13H21NO3.CH4O3S |
Molecular Weight | 335.416 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.CC[C@@H](NC(C)C)[C@@H](O)C1=CC(O)=C(O)C=C1
InChI
InChIKey=SOYAGMVKMXZVNZ-HTKOBJQYSA-N
InChI=1S/C13H21NO3.CH4O3S/c1-4-10(14-8(2)3)13(17)9-5-6-11(15)12(16)7-9;1-5(2,3)4/h5-8,10,13-17H,4H2,1-3H3;1H3,(H,2,3,4)/t10-,13+;/m1./s1
Molecular Formula | C13H21NO3 |
Molecular Weight | 239.3107 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | CH4O3S |
Molecular Weight | 96.106 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Isoetharine is a beta-2 adrenergic receptor agonist, which was developed by Max Bockmuhl, Gustav Erhart and Leonhard Stein at the Hochst laboratories of I.G. Farbenindustrie in 1934. By binding to beta-2 adrenergic receptors on bronchial cell membranes, isoetharine increases the level of cAMP and thus stimulates the relaxation of smooth-muscle cells, stabilizes mast cells and inhibits histamine release. Isoetharine was approved by FDA for the symptomatic relief of bronchiospasms in patients with chronic bronchitis or emphysema (aerosol and solution for inhalation), however, later on the drug was discontinued.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P07550|||Q53GA6|||Q9UCZ3 Gene ID: 154.0 Gene Symbol: ADRB2 Target Organism: Homo sapiens (Human) Sources: www.ncbi.nlm.nih.gov/pubmed/11283 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | BRONKOSOL Approved UseTo prevent and treat reversible bronchospasm from chronic bronchitis or emphysema. |
|||
Palliative | BRONKOSOL Approved UseTo prevent and treat reversible bronchospasm from chronic bronchitis or emphysema. |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
162 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7120101/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOETHARINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
498 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7120101/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOETHARINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7120101/ |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOETHARINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg 4 times / day multiple, oral Dose: 20 mg, 4 times / day Route: oral Route: multiple Dose: 20 mg, 4 times / day Sources: |
unhealthy, 29-72 years n = 39 Health Status: unhealthy Age Group: 29-72 years Sex: M+F Population Size: 39 Sources: |
Other AEs: Tremor, Tremor... |
5 mg 1 times / hour multiple, respiratory Dose: 5 mg, 1 times / hour Route: respiratory Route: multiple Dose: 5 mg, 1 times / hour Sources: |
unhealthy, 35 ± 3.31 years Health Status: unhealthy Age Group: 35 ± 3.31 years Sex: M+F Sources: |
Disc. AE: Nervousness... AEs leading to discontinuation/dose reduction: Nervousness (1 patient) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Tremor | 1 patient | 20 mg 4 times / day multiple, oral Dose: 20 mg, 4 times / day Route: oral Route: multiple Dose: 20 mg, 4 times / day Sources: |
unhealthy, 29-72 years n = 39 Health Status: unhealthy Age Group: 29-72 years Sex: M+F Population Size: 39 Sources: |
Tremor | 2 patients | 20 mg 4 times / day multiple, oral Dose: 20 mg, 4 times / day Route: oral Route: multiple Dose: 20 mg, 4 times / day Sources: |
unhealthy, 29-72 years n = 39 Health Status: unhealthy Age Group: 29-72 years Sex: M+F Population Size: 39 Sources: |
Nervousness | 1 patient Disc. AE |
5 mg 1 times / hour multiple, respiratory Dose: 5 mg, 1 times / hour Route: respiratory Route: multiple Dose: 5 mg, 1 times / hour Sources: |
unhealthy, 35 ± 3.31 years Health Status: unhealthy Age Group: 35 ± 3.31 years Sex: M+F Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Hypomania related to phenelzine and isoetharine interaction in one patient. | 1987 Apr |
|
A randomized, controlled comparison of isoetharine and albuterol in the treatment of acute asthma. | 1991 Oct |
|
Pharmacological treatment of chronic obstructive pulmonary disease. | 2006 |
|
Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. | 2015 Jan 5 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:13:11 GMT 2023
by
admin
on
Fri Dec 15 16:13:11 GMT 2023
|
Record UNII |
DV74WJ5PJB
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C48149
Created by
admin on Fri Dec 15 16:13:11 GMT 2023 , Edited by admin on Fri Dec 15 16:13:11 GMT 2023
|
||
|
NCI_THESAURUS |
C319
Created by
admin on Fri Dec 15 16:13:11 GMT 2023 , Edited by admin on Fri Dec 15 16:13:11 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C65976
Created by
admin on Fri Dec 15 16:13:11 GMT 2023 , Edited by admin on Fri Dec 15 16:13:11 GMT 2023
|
PRIMARY | |||
|
230-695-8
Created by
admin on Fri Dec 15 16:13:11 GMT 2023 , Edited by admin on Fri Dec 15 16:13:11 GMT 2023
|
PRIMARY | |||
|
DTXSID2045571
Created by
admin on Fri Dec 15 16:13:11 GMT 2023 , Edited by admin on Fri Dec 15 16:13:11 GMT 2023
|
PRIMARY | |||
|
DV74WJ5PJB
Created by
admin on Fri Dec 15 16:13:11 GMT 2023 , Edited by admin on Fri Dec 15 16:13:11 GMT 2023
|
PRIMARY | |||
|
76972622
Created by
admin on Fri Dec 15 16:13:11 GMT 2023 , Edited by admin on Fri Dec 15 16:13:11 GMT 2023
|
PRIMARY | |||
|
SUB02788MIG
Created by
admin on Fri Dec 15 16:13:11 GMT 2023 , Edited by admin on Fri Dec 15 16:13:11 GMT 2023
|
PRIMARY | |||
|
6024
Created by
admin on Fri Dec 15 16:13:11 GMT 2023 , Edited by admin on Fri Dec 15 16:13:11 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL1201213
Created by
admin on Fri Dec 15 16:13:11 GMT 2023 , Edited by admin on Fri Dec 15 16:13:11 GMT 2023
|
PRIMARY | |||
|
759286
Created by
admin on Fri Dec 15 16:13:11 GMT 2023 , Edited by admin on Fri Dec 15 16:13:11 GMT 2023
|
PRIMARY | |||
|
100000086437
Created by
admin on Fri Dec 15 16:13:11 GMT 2023 , Edited by admin on Fri Dec 15 16:13:11 GMT 2023
|
PRIMARY | |||
|
DBSALT000886
Created by
admin on Fri Dec 15 16:13:11 GMT 2023 , Edited by admin on Fri Dec 15 16:13:11 GMT 2023
|
PRIMARY | |||
|
7279-75-6
Created by
admin on Fri Dec 15 16:13:11 GMT 2023 , Edited by admin on Fri Dec 15 16:13:11 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |